<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666441</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-20145</org_study_id>
    <nct_id>NCT04666441</nct_id>
  </id_info>
  <brief_title>COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection</brief_title>
  <official_title>A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987&#xD;
      across different intravenous and subcutaneous doses compared to placebo.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared&#xD;
           to placebo&#xD;
&#xD;
        -  To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo&#xD;
&#xD;
        -  To assess the concentrations of REGN10933 and REGN10987 in serum over time&#xD;
&#xD;
        -  To assess the immunogenicity of REGN10933 and REGN10987&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Actual">September 21, 2021</completion_date>
  <primary_completion_date type="Actual">March 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-Weighted Average Daily Change From Day 1 in Viral Load in NP Swab Samples</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Daily Change From Day 1 in Viral Load</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Daily Change From Day 1 in Viral Load in Participants With High Viral Load at Baseline</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples. in any participant with a viral load greater than 10,000 copies/mL at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Daily Change From Day 1 in Viral Load in Participants With High Viral Load at Baseline</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples. in any participant with a viral load greater than 10,000 copies/mL at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With High Viral Load</measure>
    <time_frame>Day 1, Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
    <description>Number of participants with viral load greater than 10,000 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Viral Loads Below the Limit of Detection</measure>
    <time_frame>Day 1, Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
    <description>Number of participants with viral load less than 299 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Viral Loads Below the Lower Limit of Quantification</measure>
    <time_frame>Day 1, Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
    <description>Number of participants with viral load less than 714 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Day 1 in Viral Load as Measured by RT-qPCR in NP Swab Samples</measure>
    <time_frame>Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
    <description>Change from Day 1 in Viral Load (log10 copies/mL) as Measured by Quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) Swab Samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>Through day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infusion-Related Reactions Grade 2 or Above</measure>
    <time_frame>Through day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Injection-Site Reactions Grade 3 or Above</measure>
    <time_frame>Through day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypersensitivity Reactions Grade 2 or Above</measure>
    <time_frame>Through day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN10933 in Serum</measure>
    <time_frame>Pre-Dose, 15 minutes Post-Dose, 3 days Post-Dose, 5 days Post-Dose, 7 days Post-Dose, 120 days Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933</measure>
    <time_frame>Through day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10933</measure>
    <time_frame>Through day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN10987 in Serum</measure>
    <time_frame>Pre-Dose, 15 minutes Post-Dose, 3 days Post-Dose, 5 days Post-Dose, 7 days Post-Dose, 120 days Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10987</measure>
    <time_frame>Through day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10987</measure>
    <time_frame>Through day 120</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1149</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>IV Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy intravenous (IV) single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy IV single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy IV single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy IV single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo IV single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy subcutaneous (SC) single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy SC single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo SC single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN10933+REGN10987 combination therapy</intervention_name>
    <description>Administered IV or SC single dose</description>
    <arm_group_label>IV Dose 1</arm_group_label>
    <arm_group_label>IV Dose 2</arm_group_label>
    <arm_group_label>IV Dose 3</arm_group_label>
    <arm_group_label>IV Dose 4</arm_group_label>
    <arm_group_label>SC Dose 1</arm_group_label>
    <arm_group_label>SC Dose 2</arm_group_label>
    <other_name>REGN-COV2</other_name>
    <other_name>REGEN-COV™</other_name>
    <other_name>Ronapreve™</other_name>
    <other_name>casirivimab</other_name>
    <other_name>imdevimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV or SC single dose to match</description>
    <arm_group_label>Placebo IV Dose</arm_group_label>
    <arm_group_label>Placebo SC Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Has SARS-CoV-2-positive diagnostic test from a sample collected ≤72 hours prior to&#xD;
             randomization, as defined by the protocol&#xD;
&#xD;
          -  Low-risk symptomatic patient: Has symptoms consistent with COVID-19 (as determined by&#xD;
             the investigator) with onset ≤7 days before randomization, and meets all of the&#xD;
             following 8 criteria:&#xD;
&#xD;
               1. Age ≤50&#xD;
&#xD;
               2. No obesity, with obesity defined as BMI ≥30 kg/m2&#xD;
&#xD;
               3. Does not have cardiovascular disease or hypertension&#xD;
&#xD;
               4. Does not have chronic lung disease or asthma&#xD;
&#xD;
               5. Does not have type 1 or type 2 diabetes mellitus&#xD;
&#xD;
               6. Does not have chronic kidney disease, with or without dialysis&#xD;
&#xD;
               7. Does not have chronic liver disease&#xD;
&#xD;
               8. Is not pregnant or&#xD;
&#xD;
          -  Asymptomatic patient: Has had no symptoms consistent with COVID-19 (as determined by&#xD;
             the investigator) occurring at any time &lt;2 months prior to randomization&#xD;
&#xD;
          -  Maintains O2 saturation ≥93% on room air&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Was admitted to a hospital for COVID-19 prior to randomization, or is hospitalized&#xD;
             (inpatient) for any reason at randomization&#xD;
&#xD;
          -  Has a known positive SARS-CoV-2 serologic test&#xD;
&#xD;
          -  Has a positive SARS-CoV-2 antigen or molecular diagnostic test from a sample collected&#xD;
             &gt;72 hours prior to randomization&#xD;
&#xD;
          -  Is immunosuppressed, based on investigator's assessment&#xD;
&#xD;
          -  Has participated, or is participating, in a clinical research study evaluating&#xD;
             COVID-19 convalescent plasma, mAbs against SARS-CoV-2, or intravenous immunoglobulin&#xD;
             (IVIG) within 3 months or within 5 half-lives of the investigational product&#xD;
             (whichever is longer) prior to the screening visit&#xD;
&#xD;
          -  Prior, current, or planned future use of any of the following treatments: COVID-19&#xD;
             convalescent plasma, mAbs against SARS-CoV-2, (eg, bamlanivimab), IVIG (any&#xD;
             indication), systemic corticosteroids (any indication), or COVID-19 treatments&#xD;
             (authorized, approved, or investigational)&#xD;
&#xD;
          -  Prior use (prior to randomization), current use (at randomization), or planned use&#xD;
             (within time period given per CDC guidance but no sooner than 22 days of study drug&#xD;
             administration) of any authorized or approved vaccine for COVID-19&#xD;
&#xD;
          -  Has known active infection with influenza or other non-SARS-CoV-2 respiratory&#xD;
             pathogen, confirmed by a diagnostic test&#xD;
&#xD;
          -  Has participated, is participating, or plans to participate in a clinical research&#xD;
             study evaluating any authorized, approved, or investigational vaccine for COVID-19&#xD;
&#xD;
        NOTE: Other protocol defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010-3014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Red Oak</city>
        <state>Texas</state>
        <zip>75154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Splendora</city>
        <state>Texas</state>
        <zip>77372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <results_first_submitted>March 3, 2022</results_first_submitted>
  <results_first_submitted_qc>March 24, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2022</results_first_posted>
  <last_update_submitted>March 24, 2022</last_update_submitted>
  <last_update_submitted_qc>March 24, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) coronavirus</keyword>
  <keyword>Non-hospitalized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT04666441/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT04666441/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1186 participants were screened and 1149 participants randomized and treated. Reasons for discontinuation at screening phase: 26-Screen Failure, 8-Subject Decision, 1-Sponsor Request, 1-Other. 1 randomized participant was not treated due to lack of supplies.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo IV Dose</title>
          <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
        </group>
        <group group_id="P2">
          <title>300mg IV</title>
          <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="P3">
          <title>600mg IV</title>
          <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="P4">
          <title>1200mg IV</title>
          <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="P5">
          <title>2400mg IV</title>
          <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="P6">
          <title>Placebo SC Dose</title>
          <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
        </group>
        <group group_id="P7">
          <title>600mg SC</title>
          <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="P8">
          <title>1200mg SC</title>
          <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="162"/>
                <participants group_id="P4" count="165"/>
                <participants group_id="P5" count="166"/>
                <participants group_id="P6" count="82"/>
                <participants group_id="P7" count="163"/>
                <participants group_id="P8" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="161"/>
                <participants group_id="P5" count="166"/>
                <participants group_id="P6" count="79"/>
                <participants group_id="P7" count="158"/>
                <participants group_id="P8" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants who received any study drug; based on the treatment received (as treated)</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo IV Dose</title>
          <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
        </group>
        <group group_id="B2">
          <title>300mg IV</title>
          <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="B3">
          <title>600mg IV</title>
          <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="B4">
          <title>1200mg IV</title>
          <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="B5">
          <title>2400mg IV</title>
          <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="B6">
          <title>Placebo SC Dose</title>
          <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
        </group>
        <group group_id="B7">
          <title>600mg SC</title>
          <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="B8">
          <title>1200mg SC</title>
          <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="162"/>
            <count group_id="B4" value="165"/>
            <count group_id="B5" value="166"/>
            <count group_id="B6" value="82"/>
            <count group_id="B7" value="163"/>
            <count group_id="B8" value="164"/>
            <count group_id="B9" value="1149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="162"/>
                    <count group_id="B4" value="165"/>
                    <count group_id="B5" value="166"/>
                    <count group_id="B6" value="82"/>
                    <count group_id="B7" value="163"/>
                    <count group_id="B8" value="164"/>
                    <count group_id="B9" value="1149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="10.15"/>
                    <measurement group_id="B2" value="33.9" spread="8.99"/>
                    <measurement group_id="B3" value="34.2" spread="10.08"/>
                    <measurement group_id="B4" value="34.4" spread="9.81"/>
                    <measurement group_id="B5" value="33.9" spread="9.24"/>
                    <measurement group_id="B6" value="36.3" spread="9.88"/>
                    <measurement group_id="B7" value="33.5" spread="9.50"/>
                    <measurement group_id="B8" value="33.0" spread="10.18"/>
                    <measurement group_id="B9" value="34.0" spread="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="162"/>
                    <count group_id="B4" value="165"/>
                    <count group_id="B5" value="166"/>
                    <count group_id="B6" value="82"/>
                    <count group_id="B7" value="163"/>
                    <count group_id="B8" value="164"/>
                    <count group_id="B9" value="1149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="91"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="82"/>
                    <measurement group_id="B8" value="85"/>
                    <measurement group_id="B9" value="600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="81"/>
                    <measurement group_id="B8" value="79"/>
                    <measurement group_id="B9" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="162"/>
                    <count group_id="B4" value="165"/>
                    <count group_id="B5" value="166"/>
                    <count group_id="B6" value="82"/>
                    <count group_id="B7" value="163"/>
                    <count group_id="B8" value="164"/>
                    <count group_id="B9" value="1149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="68"/>
                    <measurement group_id="B8" value="62"/>
                    <measurement group_id="B9" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="91"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="94"/>
                    <measurement group_id="B8" value="99"/>
                    <measurement group_id="B9" value="684"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="162"/>
                    <count group_id="B4" value="165"/>
                    <count group_id="B5" value="166"/>
                    <count group_id="B6" value="82"/>
                    <count group_id="B7" value="163"/>
                    <count group_id="B8" value="164"/>
                    <count group_id="B9" value="1149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="141"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B7" value="141"/>
                    <measurement group_id="B8" value="136"/>
                    <measurement group_id="B9" value="966"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Viral Load in Nasopharyngeal Swab Samples</title>
          <population>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) results from central lab</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="162"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="164"/>
                    <count group_id="B5" value="164"/>
                    <count group_id="B6" value="81"/>
                    <count group_id="B7" value="162"/>
                    <count group_id="B8" value="164"/>
                    <count group_id="B9" value="1138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.98" spread="2.753"/>
                    <measurement group_id="B2" value="6.20" spread="2.697"/>
                    <measurement group_id="B3" value="5.70" spread="3.171"/>
                    <measurement group_id="B4" value="5.87" spread="2.656"/>
                    <measurement group_id="B5" value="6.12" spread="2.521"/>
                    <measurement group_id="B6" value="6.28" spread="2.521"/>
                    <measurement group_id="B7" value="6.15" spread="2.481"/>
                    <measurement group_id="B8" value="5.90" spread="2.832"/>
                    <measurement group_id="B9" value="6.01" spread="2.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-Weighted Average Daily Change From Day 1 in Viral Load in NP Swab Samples</title>
        <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Daily Change From Day 1 in Viral Load in NP Swab Samples</title>
          <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
          <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
          <units>log10 copies/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="71"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="0.11"/>
                    <measurement group_id="O2" value="-2.25" spread="0.11"/>
                    <measurement group_id="O3" value="-2.34" spread="0.12"/>
                    <measurement group_id="O4" value="-2.24" spread="0.12"/>
                    <measurement group_id="O5" value="-2.40" spread="0.12"/>
                    <measurement group_id="O6" value="-2.24" spread="0.12"/>
                    <measurement group_id="O7" value="-2.24" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average Daily Change From Day 1 in Viral Load</title>
        <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
        <time_frame>Day 1 to Day 5</time_frame>
        <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Daily Change From Day 1 in Viral Load</title>
          <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
          <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
          <units>log10 copies/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="99"/>
                <count group_id="O7" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.09"/>
                    <measurement group_id="O2" value="-1.66" spread="0.09"/>
                    <measurement group_id="O3" value="-1.76" spread="0.09"/>
                    <measurement group_id="O4" value="-1.77" spread="0.09"/>
                    <measurement group_id="O5" value="-1.68" spread="0.10"/>
                    <measurement group_id="O6" value="-1.56" spread="0.09"/>
                    <measurement group_id="O7" value="-1.61" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0040</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average Daily Change From Day 1 in Viral Load in Participants With High Viral Load at Baseline</title>
        <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples. in any participant with a viral load greater than 10,000 copies/mL at baseline.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>Overall modified Full Analysis Set (Overall mFAS): All randomized participants with a positive central-lab determined SARS-CoV-2 RT-qPCR result from NP swab samples at randomization; based on the treatment received (as treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Daily Change From Day 1 in Viral Load in Participants With High Viral Load at Baseline</title>
          <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples. in any participant with a viral load greater than 10,000 copies/mL at baseline.</description>
          <population>Overall modified Full Analysis Set (Overall mFAS): All randomized participants with a positive central-lab determined SARS-CoV-2 RT-qPCR result from NP swab samples at randomization; based on the treatment received (as treated)</population>
          <units>log10 copies/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="128"/>
                <count group_id="O5" value="136"/>
                <count group_id="O6" value="133"/>
                <count group_id="O7" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Viral Load is &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="124"/>
                    <count group_id="O5" value="133"/>
                    <count group_id="O6" value="131"/>
                    <count group_id="O7" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="0.09"/>
                    <measurement group_id="O2" value="-2.36" spread="0.09"/>
                    <measurement group_id="O3" value="-2.37" spread="0.09"/>
                    <measurement group_id="O4" value="-2.41" spread="0.09"/>
                    <measurement group_id="O5" value="-2.34" spread="0.09"/>
                    <measurement group_id="O6" value="-2.30" spread="0.09"/>
                    <measurement group_id="O7" value="-2.27" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Viral Load is &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="105"/>
                    <count group_id="O4" value="109"/>
                    <count group_id="O5" value="111"/>
                    <count group_id="O6" value="116"/>
                    <count group_id="O7" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="0.09"/>
                    <measurement group_id="O2" value="-2.47" spread="0.09"/>
                    <measurement group_id="O3" value="-2.51" spread="0.10"/>
                    <measurement group_id="O4" value="-2.49" spread="0.09"/>
                    <measurement group_id="O5" value="-2.46" spread="0.09"/>
                    <measurement group_id="O6" value="-2.40" spread="0.09"/>
                    <measurement group_id="O7" value="-2.38" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Viral Load is &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="94"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="0.10"/>
                    <measurement group_id="O2" value="-2.62" spread="0.10"/>
                    <measurement group_id="O3" value="-2.63" spread="0.10"/>
                    <measurement group_id="O4" value="-2.64" spread="0.10"/>
                    <measurement group_id="O5" value="-2.62" spread="0.10"/>
                    <measurement group_id="O6" value="-2.47" spread="0.10"/>
                    <measurement group_id="O7" value="-2.52" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Viral Load is &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="71"/>
                    <count group_id="O7" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="0.11"/>
                    <measurement group_id="O2" value="-2.77" spread="0.11"/>
                    <measurement group_id="O3" value="-2.83" spread="0.11"/>
                    <measurement group_id="O4" value="-2.82" spread="0.12"/>
                    <measurement group_id="O5" value="-2.72" spread="0.11"/>
                    <measurement group_id="O6" value="-2.52" spread="0.11"/>
                    <measurement group_id="O7" value="-2.73" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average Daily Change From Day 1 in Viral Load in Participants With High Viral Load at Baseline</title>
        <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples. in any participant with a viral load greater than 10,000 copies/mL at baseline.</description>
        <time_frame>Day 1 to Day 5</time_frame>
        <population>Overall modified Full Analysis Set (Overall mFAS): All randomized participants with a positive central-lab determined SARS-CoV-2 RT-qPCR result from NP swab samples at randomization; based on the treatment received (as treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Daily Change From Day 1 in Viral Load in Participants With High Viral Load at Baseline</title>
          <description>Time-weighted average daily change from Day 1 in viral load (log10 copies/mL) as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples. in any participant with a viral load greater than 10,000 copies/mL at baseline.</description>
          <population>Overall modified Full Analysis Set (Overall mFAS): All randomized participants with a positive central-lab determined SARS-CoV-2 RT-qPCR result from NP swab samples at randomization; based on the treatment received (as treated)</population>
          <units>log10 copies/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="124"/>
                <count group_id="O5" value="132"/>
                <count group_id="O6" value="128"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Viral Load is &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="124"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="128"/>
                    <count group_id="O7" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.08"/>
                    <measurement group_id="O2" value="-1.69" spread="0.08"/>
                    <measurement group_id="O3" value="-1.73" spread="0.09"/>
                    <measurement group_id="O4" value="-1.76" spread="0.09"/>
                    <measurement group_id="O5" value="-1.68" spread="0.08"/>
                    <measurement group_id="O6" value="-1.62" spread="0.08"/>
                    <measurement group_id="O7" value="-1.61" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Viral Load is &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="109"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="114"/>
                    <count group_id="O7" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.08"/>
                    <measurement group_id="O2" value="-1.77" spread="0.08"/>
                    <measurement group_id="O3" value="-1.83" spread="0.09"/>
                    <measurement group_id="O4" value="-1.81" spread="0.09"/>
                    <measurement group_id="O5" value="-1.76" spread="0.09"/>
                    <measurement group_id="O6" value="-1.69" spread="0.08"/>
                    <measurement group_id="O7" value="-1.69" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Viral Load is &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="94"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="91"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.09"/>
                    <measurement group_id="O2" value="-1.89" spread="0.09"/>
                    <measurement group_id="O3" value="-1.92" spread="0.09"/>
                    <measurement group_id="O4" value="-1.93" spread="0.09"/>
                    <measurement group_id="O5" value="-1.91" spread="0.09"/>
                    <measurement group_id="O6" value="-1.76" spread="0.09"/>
                    <measurement group_id="O7" value="-1.79" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Viral Load is &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="67"/>
                    <count group_id="O6" value="69"/>
                    <count group_id="O7" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="0.11"/>
                    <measurement group_id="O2" value="-1.99" spread="0.10"/>
                    <measurement group_id="O3" value="-2.08" spread="0.10"/>
                    <measurement group_id="O4" value="-2.08" spread="0.11"/>
                    <measurement group_id="O5" value="-2.01" spread="0.10"/>
                    <measurement group_id="O6" value="-1.76" spread="0.10"/>
                    <measurement group_id="O7" value="-1.97" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0120</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^4 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^5 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^6 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Baseline Viral Load &gt;10^7 copies/mL Difference vs. Placebo (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With High Viral Load</title>
        <description>Number of participants with viral load greater than 10,000 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
        <time_frame>Day 1, Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
        <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High Viral Load</title>
          <description>Number of participants with viral load greater than 10,000 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
          <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="103"/>
                <count group_id="O7" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Viral Load &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="99"/>
                    <measurement group_id="O7" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Viral Load &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="93"/>
                    <measurement group_id="O7" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Viral Load &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="81"/>
                    <measurement group_id="O7" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Viral Load &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="63"/>
                    <measurement group_id="O7" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Viral Load &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="89"/>
                    <measurement group_id="O7" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Viral Load &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="68"/>
                    <measurement group_id="O7" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Viral Load &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Viral Load &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 Viral Load &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="55"/>
                    <measurement group_id="O6" value="62"/>
                    <measurement group_id="O7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 Viral Load &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 Viral Load &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 Viral Load &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Viral Load &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Viral Load &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Viral Load &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Viral Load &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Viral Load &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Viral Load &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Viral Load &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Viral Load &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Viral Load &gt;10^4 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Viral Load &gt;10^5 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Viral Load &gt;10^6 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Viral Load &gt;10^7 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Viral Loads Below the Limit of Detection</title>
        <description>Number of participants with viral load less than 299 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
        <time_frame>Day 1, Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
        <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Loads Below the Limit of Detection</title>
          <description>Number of participants with viral load less than 299 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
          <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="103"/>
                <count group_id="O7" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="67"/>
                    <measurement group_id="O7" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="81"/>
                    <measurement group_id="O7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Viral Loads Below the Lower Limit of Quantification</title>
        <description>Number of participants with viral load less than 714 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
        <time_frame>Day 1, Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
        <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Loads Below the Lower Limit of Quantification</title>
          <description>Number of participants with viral load less than 714 copies/mL, as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.</description>
          <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="103"/>
                <count group_id="O7" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="76"/>
                    <measurement group_id="O7" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="87"/>
                    <measurement group_id="O7" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Day 1 in Viral Load as Measured by RT-qPCR in NP Swab Samples</title>
        <description>Change from Day 1 in Viral Load (log10 copies/mL) as Measured by Quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) Swab Samples</description>
        <time_frame>Day 3, Day 5, Day 7, Day 15, Day 22</time_frame>
        <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 1 in Viral Load as Measured by RT-qPCR in NP Swab Samples</title>
          <description>Change from Day 1 in Viral Load (log10 copies/mL) as Measured by Quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) Swab Samples</description>
          <population>Seronegative modified Full Analysis Set (Seronegative mFAS): Participants in the Full Analysis Set (Overall mFAS) who were seronegative at baseline</population>
          <units>log10 copies/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="103"/>
                <count group_id="O7" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3 change from Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.13"/>
                    <measurement group_id="O2" value="-1.71" spread="0.13"/>
                    <measurement group_id="O3" value="-1.91" spread="0.14"/>
                    <measurement group_id="O4" value="-1.85" spread="0.14"/>
                    <measurement group_id="O5" value="-1.69" spread="0.14"/>
                    <measurement group_id="O6" value="-1.55" spread="0.13"/>
                    <measurement group_id="O7" value="-1.65" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 change from Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="0.16"/>
                    <measurement group_id="O2" value="-3.24" spread="0.16"/>
                    <measurement group_id="O3" value="-3.37" spread="0.16"/>
                    <measurement group_id="O4" value="-3.32" spread="0.17"/>
                    <measurement group_id="O5" value="-3.33" spread="0.17"/>
                    <measurement group_id="O6" value="-3.19" spread="0.16"/>
                    <measurement group_id="O7" value="-3.20" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 change from Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.44" spread="0.16"/>
                    <measurement group_id="O2" value="-4.24" spread="0.16"/>
                    <measurement group_id="O3" value="-4.08" spread="0.16"/>
                    <measurement group_id="O4" value="-4.10" spread="0.17"/>
                    <measurement group_id="O5" value="-4.17" spread="0.17"/>
                    <measurement group_id="O6" value="-4.33" spread="0.16"/>
                    <measurement group_id="O7" value="-4.04" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 change from Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="100"/>
                    <count group_id="O7" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.66" spread="0.16"/>
                    <measurement group_id="O2" value="-6.11" spread="0.16"/>
                    <measurement group_id="O3" value="-5.97" spread="0.17"/>
                    <measurement group_id="O4" value="-5.91" spread="0.17"/>
                    <measurement group_id="O5" value="-5.77" spread="0.17"/>
                    <measurement group_id="O6" value="-6.17" spread="0.17"/>
                    <measurement group_id="O7" value="-6.05" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 change from Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.27" spread="0.13"/>
                    <measurement group_id="O2" value="-6.58" spread="0.14"/>
                    <measurement group_id="O3" value="-6.50" spread="0.14"/>
                    <measurement group_id="O4" value="-6.56" spread="0.14"/>
                    <measurement group_id="O5" value="-6.36" spread="0.15"/>
                    <measurement group_id="O6" value="-6.69" spread="0.14"/>
                    <measurement group_id="O7" value="-6.60" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 3 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 3 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 3 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 3 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 3 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0696</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 3 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0187</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 5 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 5 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-1.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.53</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 5 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 5 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>-0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 5 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 5 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 7 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 7 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 7 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 7 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 7 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 7 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 15 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0515</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 15 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1864</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 15 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2866</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 15 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6470</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 15 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0280</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 15 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0854</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 22 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1078</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 22 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2235</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 22 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1369</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 22 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6610</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 22 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0284</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Difference vs. Placebo, by Day 22 (log10 copies/mL)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0800</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</title>
        <time_frame>Through day 29</time_frame>
        <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo IV Dose</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>Placebo SC Dose</title>
            <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O8">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</title>
          <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="163"/>
                <count group_id="O8" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infusion-Related Reactions Grade 2 or Above</title>
        <time_frame>Through day 4</time_frame>
        <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo IV Dose</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>Placebo SC Dose</title>
            <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O8">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infusion-Related Reactions Grade 2 or Above</title>
          <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="163"/>
                <count group_id="O8" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Injection-Site Reactions Grade 3 or Above</title>
        <time_frame>Through day 4</time_frame>
        <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo IV Dose</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>Placebo SC Dose</title>
            <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O8">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions Grade 3 or Above</title>
          <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="163"/>
                <count group_id="O8" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypersensitivity Reactions Grade 2 or Above</title>
        <time_frame>Through day 29</time_frame>
        <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo IV Dose</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>Placebo SC Dose</title>
            <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O8">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypersensitivity Reactions Grade 2 or Above</title>
          <population>Safety Analysis Set (SAF): Randomized participants who received any study drug; based on the treatment received (as treated)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="163"/>
                <count group_id="O8" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of REGN10933 in Serum</title>
        <time_frame>Pre-Dose, 15 minutes Post-Dose, 3 days Post-Dose, 5 days Post-Dose, 7 days Post-Dose, 120 days Post-Dose</time_frame>
        <population>Number Analyzed = number of participants contributing to each nominal timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of REGN10933 in Serum</title>
          <population>Number Analyzed = number of participants contributing to each nominal timepoint</population>
          <units>milligrams per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="166"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="160"/>
                    <count group_id="O6" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.529" spread="4.51"/>
                    <measurement group_id="O2" value="1.95" spread="12.1"/>
                    <measurement group_id="O3" value="0.847" spread="6.28"/>
                    <measurement group_id="O4" value="13.3" spread="130"/>
                    <measurement group_id="O5" value="0.992" spread="12.5"/>
                    <measurement group_id="O6" value="0.395" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="163"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" spread="52.1"/>
                    <measurement group_id="O2" value="95.8" spread="57.9"/>
                    <measurement group_id="O3" value="178" spread="118"/>
                    <measurement group_id="O4" value="375" spread="267"/>
                    <measurement group_id="O5" value="8.73" spread="52.7"/>
                    <measurement group_id="O6" value="3.89" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="15.7"/>
                    <measurement group_id="O2" value="54.9" spread="19.2"/>
                    <measurement group_id="O3" value="109" spread="37.9"/>
                    <measurement group_id="O4" value="223" spread="63.9"/>
                    <measurement group_id="O5" value="22.4" spread="18.3"/>
                    <measurement group_id="O6" value="41.0" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="160"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="154"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="16.8"/>
                    <measurement group_id="O2" value="46.6" spread="16.9"/>
                    <measurement group_id="O3" value="88.4" spread="27.8"/>
                    <measurement group_id="O4" value="186" spread="53.3"/>
                    <measurement group_id="O5" value="26.3" spread="10.7"/>
                    <measurement group_id="O6" value="54.9" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="161"/>
                    <count group_id="O5" value="159"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="13.5"/>
                    <measurement group_id="O2" value="39.8" spread="11.5"/>
                    <measurement group_id="O3" value="82.8" spread="26.3"/>
                    <measurement group_id="O4" value="164" spread="46.0"/>
                    <measurement group_id="O5" value="26.8" spread="9.65"/>
                    <measurement group_id="O6" value="54.6" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="149"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="1.13"/>
                    <measurement group_id="O2" value="3.25" spread="1.88"/>
                    <measurement group_id="O3" value="6.46" spread="4.74"/>
                    <measurement group_id="O4" value="12.3" spread="8.42"/>
                    <measurement group_id="O5" value="2.73" spread="1.89"/>
                    <measurement group_id="O6" value="5.64" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933</title>
        <time_frame>Through day 120</time_frame>
        <population>ADA analysis set includes all treated participants who received any amount of study drug and had at least one non-missing antibody variables result following the first dose of study drug or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933</title>
          <population>ADA analysis set includes all treated participants who received any amount of study drug and had at least one non-missing antibody variables result following the first dose of study drug or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="147"/>
                <count group_id="O7" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-existing Immunoreactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Boosted Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Emergent Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="143"/>
                    <measurement group_id="O5" value="147"/>
                    <measurement group_id="O6" value="132"/>
                    <measurement group_id="O7" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10933</title>
        <time_frame>Through day 120</time_frame>
        <population>NAb analysis set includes all treated participants who received any study drug, had at least one non-missing antibody result following the first dose of study drug, and either tested negative at all ADA sampling times or tested positive for ADA with at least one non-missing NAb result after first dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10933</title>
          <population>NAb analysis set includes all treated participants who received any study drug, had at least one non-missing antibody result following the first dose of study drug, and either tested negative at all ADA sampling times or tested positive for ADA with at least one non-missing NAb result after first dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="147"/>
                <count group_id="O7" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-emergent &amp; Treatment-boosted; Negative in NAb assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent &amp; Treatment-boosted; Positive in NAb assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="143"/>
                    <measurement group_id="O5" value="147"/>
                    <measurement group_id="O6" value="132"/>
                    <measurement group_id="O7" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of REGN10987 in Serum</title>
        <time_frame>Pre-Dose, 15 minutes Post-Dose, 3 days Post-Dose, 5 days Post-Dose, 7 days Post-Dose, 120 days Post-Dose</time_frame>
        <population>Number Analyzed = number of participants contributing to each nominal timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of REGN10987 in Serum</title>
          <population>Number Analyzed = number of participants contributing to each nominal timepoint</population>
          <units>milligrams per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="166"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="160"/>
                    <count group_id="O6" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.529" spread="4.38"/>
                    <measurement group_id="O2" value="2.04" spread="12.7"/>
                    <measurement group_id="O3" value="0.823" spread="6.48"/>
                    <measurement group_id="O4" value="13.1" spread="126"/>
                    <measurement group_id="O5" value="1.02" spread="12.8"/>
                    <measurement group_id="O6" value="0.370" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="163"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="53.1"/>
                    <measurement group_id="O2" value="95.4" spread="59.4"/>
                    <measurement group_id="O3" value="178" spread="119"/>
                    <measurement group_id="O4" value="383" spread="273"/>
                    <measurement group_id="O5" value="8.48" spread="51.7"/>
                    <measurement group_id="O6" value="4.36" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="15.9"/>
                    <measurement group_id="O2" value="56.0" spread="18.9"/>
                    <measurement group_id="O3" value="109" spread="38.5"/>
                    <measurement group_id="O4" value="225" spread="62.3"/>
                    <measurement group_id="O5" value="21.8" spread="16.2"/>
                    <measurement group_id="O6" value="42.0" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="160"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="154"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="15.5"/>
                    <measurement group_id="O2" value="46.3" spread="15.9"/>
                    <measurement group_id="O3" value="87.1" spread="26.9"/>
                    <measurement group_id="O4" value="177" spread="50.9"/>
                    <measurement group_id="O5" value="25.6" spread="9.31"/>
                    <measurement group_id="O6" value="52.9" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="161"/>
                    <count group_id="O5" value="159"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="12.8"/>
                    <measurement group_id="O2" value="38.0" spread="11.2"/>
                    <measurement group_id="O3" value="77.7" spread="24.3"/>
                    <measurement group_id="O4" value="151" spread="43.1"/>
                    <measurement group_id="O5" value="26.2" spread="8.74"/>
                    <measurement group_id="O6" value="53.7" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 days Post-Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="149"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.805"/>
                    <measurement group_id="O2" value="1.97" spread="1.38"/>
                    <measurement group_id="O3" value="3.80" spread="3.10"/>
                    <measurement group_id="O4" value="6.88" spread="5.47"/>
                    <measurement group_id="O5" value="1.63" spread="1.43"/>
                    <measurement group_id="O6" value="3.26" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10987</title>
        <time_frame>Through day 120</time_frame>
        <population>ADA analysis set includes all treated participants who received any amount of study drug and had at least one non-missing antibody variables result following the first dose of study drug or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10987</title>
          <population>ADA analysis set includes all treated participants who received any amount of study drug and had at least one non-missing antibody variables result following the first dose of study drug or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="147"/>
                <count group_id="O7" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-existing Immunoreactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Boosted Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Emergent Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="133"/>
                    <measurement group_id="O5" value="140"/>
                    <measurement group_id="O6" value="121"/>
                    <measurement group_id="O7" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10987</title>
        <time_frame>Through day 120</time_frame>
        <population>NAb analysis set includes all treated participants who received any study drug, had at least one non-missing antibody result following the first dose of study drug, and either tested negative at all ADA sampling times or tested positive for ADA with at least one non-missing NAb result after first dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (IV + SC)</title>
            <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987 or a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
          </group>
          <group group_id="O2">
            <title>300mg IV</title>
            <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O3">
            <title>600mg IV</title>
            <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O4">
            <title>1200mg IV</title>
            <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O5">
            <title>2400mg IV</title>
            <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O6">
            <title>600mg SC</title>
            <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
          <group group_id="O7">
            <title>1200mg SC</title>
            <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10987</title>
          <population>NAb analysis set includes all treated participants who received any study drug, had at least one non-missing antibody result following the first dose of study drug, and either tested negative at all ADA sampling times or tested positive for ADA with at least one non-missing NAb result after first dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="147"/>
                <count group_id="O7" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-existing Immunoreactivity; Negative in NAb assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent &amp; Treatment-boosted; Negative in NAb assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent &amp; Treatment-boosted; Positive in NAb assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="133"/>
                    <measurement group_id="O5" value="140"/>
                    <measurement group_id="O6" value="121"/>
                    <measurement group_id="O7" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug to Day 169</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo IV</title>
          <description>Participants received a single intravenous dose of placebo matching REGN10933+REGN10987</description>
        </group>
        <group group_id="E2">
          <title>REGN10933 + REGN10987 300 mg IV</title>
          <description>Participants received a single 300mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="E3">
          <title>REGN10933 + REGN10987 600 mg IV</title>
          <description>Participants received a single 600mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="E4">
          <title>REGN10933 + REGN10987 1200 mg IV</title>
          <description>Participants received a single 1200mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="E5">
          <title>REGN10933 + REGN10987 2400 mg IV</title>
          <description>Participants received a single 2400mg intravenous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="E6">
          <title>Placebo SC</title>
          <description>Participants received a single subcutaneous dose of placebo matching REGN10933+REGN10987</description>
        </group>
        <group group_id="E7">
          <title>REGN10933 + REGN10987 600 mg SC</title>
          <description>Participants received a single 600mg subcutaneous dose of REGN10933+REGN10987</description>
        </group>
        <group group_id="E8">
          <title>REGN10933 + REGN10987 1200 mg SC</title>
          <description>Participants received a single 1200mg subcutaneous dose of REGN10933+REGN10987</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (24.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (24.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="163"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E3" events="28" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E4" events="29" subjects_affected="28" subjects_at_risk="165"/>
                <counts group_id="E5" events="18" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E7" events="19" subjects_affected="18" subjects_at_risk="163"/>
                <counts group_id="E8" events="21" subjects_affected="21" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Administrator</name_or_title>
      <organization>Regeneron Pharmaceuticals, Inc.</organization>
      <phone>844-734-6643</phone>
      <email>clinicaltrials@regeneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

